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Summary
Clostridioides (Clostridium) difﬁcile presents a significant health risk to humans and animals. The complexity of the bacterial–host interaction affecting
pathogenesis and disease development creates an
ongoing challenge for epidemiological studies, control strategies and prevention planning. The recent
emergence of human disease caused by strains of C.
difﬁcile found in animals adds to mounting evidence
that C. difﬁcile infection (CDI) may be a zoonosis. In
equine populations, C. difﬁcile is a known cause of
diarrhoea and gastrointestinal inﬂammation, with
considerable mortality and morbidity. This has a signiﬁcant impact on both the well-being of the animal
and, in the case of performance and production animals, it may have an adverse economic impact on
relevant industries. While C. difﬁcile is regularly isolated from horses, many questions remain regarding
the impact of asymptomatic carriage as well as
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optimization of diagnosis, testing and treatment. This
review provides an overview of our understanding of
equine CDI while also identifying knowledge gaps
and the need for a holistic One Health approach to a
complicated issue.
Introduction
First isolated in 1935 from the intestinal ﬂora of human
infants, Clostridioides (Clostridium) difﬁcile was initially
considered a commensal (Hall and O’Toole, 1935). This
perception remained for four decades until C. difﬁcile
was ﬁnally identiﬁed as a causative agent of
antimicrobial-related diarrhoea and life-threatening pseudomembranous colitis (Bartlett et al., 1978; Larson
et al., 1978). Today, C. difﬁcile is recognized as a major
cause of gastrointestinal disease affecting both animals
and humans, with its ubiquity in the environment becoming increasingly apparent (Lim et al., 2020).
In human populations, C. difﬁcile is the most common
cause of infectious healthcare-associated diarrhoea with
the rate of severe cases increasing (McDonald
et al., 2018). In the last 20 years, however, focus has
turned to the role of C. difﬁcile in animal gastrointestinal
disease and the role of animal populations in the ampliﬁcation and transmission of C. difﬁcile. High prevalence of
C. difﬁcile has been consistently reported globally in both
swine (mean 43%, range 0%–100%) and cattle (mean
14%, range 0.5%–56.4%), with a 2014 study conﬁrming
the relatedness of strains isolated from paired pig and
farmer samples (Knetsch et al., 2014; Knight and
Riley, 2019). Further genomic studies have provided
compelling evidence for a novel zoonotic paradigm for C.
difﬁcile infection (CDI) (Knight et al., 2017; Knight
et al., 2019). A 2017 study strengthened this animal–
human link, identifying a signiﬁcant association between
proximity to livestock farms and the occurrence of
community-acquired CDI case clusters (Anderson
et al., 2017). These key aspects have led to a deeper
consideration of the impact of C. difﬁcile in a wider range
of animal populations.
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In horses there are three inter-related issues pertaining
to C. difﬁcile. Primarily there is an animal welfare concern; disease in horses due to C. difﬁcile can cause discomfort in its mildest form and debilitating complications
and death at its most severe. Horses are, however, also
intertwined with human activity; used as performance,
work and companion animals. In 2018/19, the horse racing industry in Australia reportedly contributed AU$9.3 billion to the Australian GDP (Racing Australia, 2020) The
socio-economic impact of CDI on racing, breeding and
other equine-related industries is therefore potentially of
great signiﬁcance. Finally, in the One Health era, which
acknowledges the link between human health, animal
health and the environment, the role of horses in the dissemination and dispersal of C. difﬁcile to the wider community and environment needs to be considered. The
review outlines our current understanding of C. difﬁcile
and CDI within equine populations. It reﬂects on the
knowledge gaps and diagnostic shortfalls evident within
this emerging ﬁeld and the importance of adopting a One
Health approach to achieve effective infection prevention
and control and improved health outcomes for humans
and animals alike.
Pathophysiology
The pathophysiology of CDI is similar in horses compared to humans and other animals. CDI refers to the colonization of C. difﬁcile within the host tissue. Disease
associated with CDI is toxin-mediated and exhibits a
broad spectrum of signs and symptoms. Mild cases manifest as watery diarrhoea and low-grade fever. Further
infection development may result in a progression to
severe CDI, with additional features of haemodynamic
instability, pseudomembranous colitis and severe
anorexia (Bartlett et al., 1978). In horses, C. difﬁcile is
also a known cause of duodenitis-proximal jejunitis and
necrotizing enteritis (Arroyo et al., 2004; Arroyo
et al., 2017). Extracolonic manifestations such as bacteremia and organ failure can also develop and extreme
cases can result in death (Dallal et al., 2002; Arroyo
et al., 2004; Napolitano and Edmiston, 2017).
Transmission of C. difﬁcile occurs through the faecal–
oral route. Ingested spores pass to the bowel where bile
acids stimulate germination into vegetative cells (Francis
et al., 2013). These cells proliferate in the intestinal
anaerobic environment, penetrating the mucus layer to
attach to the host epithelial cells. Following attachment,
toxigenic strains produce toxins that interfere with cell
signalling, disrupting the cytoskeleton resulting in cell
damage, loss of tight junction integrity and apoptosis
(Hecht et al., 1992). This damage induces inﬂammatory
mediator release and ﬂuid secretion which manifests as
watery diarrhoea (Pruitt and Lacy, 2012).

Colonization and lesion development associated with
host inﬂammatory response to CDI occurs within the
intestinal tract; however, the exact location varies
between animal species and stage of life (Keel and
Songer, 2006). In neonatal foals (≤1 month old), lesions
are predominantly located within the small intestine with
extended formation within the large intestine less frequent (Keel and Songer, 2006; Diab et al., 2013b). Conversely, lesion development in older foals and adult
horses appears to be restricted to the cecum and
ascending colon of the large intestine (Keel and
Songer, 2006).
Clinical manifestations may be self-resolving or
chronic. Despite recurrent CDI occurring in 20%–30% of
human C. difﬁcile cases, recurrent CDI has not been
noted as an ongoing issue in equine populations (Weese
et al., 2006; Cornely et al., 2012). A lack of long-term surveillance of C. difﬁcile and CDI in horses, however, may
be impacting this view. Asymptomatic infection can also
occur resulting in the shedding of viable spores in the
absence of disease, contributing to contamination of the
environment (Båverud et al., 2003). This complexity creates difﬁculty in discerning between states of carriage,
colonization and infection. Further investigation into this
complexity and the disparity of disease impact within and
between species may indeed lead to further understanding of C. difﬁcile pathophysiological nuances
(Weese, 2020).
Pathogenicity
The pathogenicity of C. difﬁcile is attributed to the production of potent toxins as well as the ability to form
hardy endospores, and these characteristics may appear
in human, animal and environmental strains alike. Toxigenicity is inﬂuenced by the presence of the Pathogenicity Locus (PaLoc) – a 19.6 kb chromosomal region that
encodes toxin A (tcdA) and toxin B (tcdB), as well as
positive and negative regulators for toxin expression
(tcdR and tcdC respectively) (Braun et al., 1996; Knight
et al., 2015b). The presence of an additional binary toxin
(C. difﬁcile transferase, CDT), thought to enhance pathogenicity, has also become increasingly signiﬁcant in the
last two decades. CDT appears to be highly prevalent in
animal strains (Knight et al., 2013; Gerding et al., 2014;
Knight et al., 2015a). The genetic architecture of the C.
difﬁcile PaLoc and binary toxin locus (CdtLoc) is shown
in Fig. 1. While toxigenic strains of C. difﬁcile are
undoubtedly important due to their association with symptomatic disease, it has been demonstrated experimentally
that acquisition of the C. difﬁcile PaLoc region by nontoxigenic strains can occur via horizontal gene transfer
(HGT), although the frequency at which this occurs is not
known (Brouwer et al., 2013; Elliott et al., 2014; Candel-
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Fig. 1. Schematic diagram of the C.
difﬁcile PaLoc and CdtLoc chromosomal regions which encode for virulence factors, toxin A and toxin B,
and
binary
toxin
respectively.
Adapted from Francis et al. (2013)
and Elliott et al. (2017).

Pérez et al., 2019). Recombination and HGT are thought
to have played a signiﬁcant role in the evolution of
‘hyper-virulent’ C. difﬁcile strains seen today, including
PCR ribotype (RT) 027 which caused human CDI epidemics in Canada, the USA and Europe and has been
isolated from horses (Songer et al., 2009; He
et al., 2013). Genomic studies have determined that
approximately 11% of the C. difﬁcile genome is comprised of mobile genetic elements including transposons
and plasmids carrying antimicrobial resistance (AMR)
genes (Sebaihia et al., 2006).
Non-toxigenic strains of C. difﬁcile are also thought to
have a protective function against toxigenic strains
(Natarajan et al., 2013). Although this is yet to be investigated in equine populations, protection has been seen
experimentally in pigs (Songer et al., 2007; Oliveira
Júnior et al., 2019). This attribute could potentially be
exploited in the production of preventative medications or
vaccines, as seen with the non-toxigenic C. difﬁcile
human strain, NTCD-M3, which is showing promising
results in phase II human trials for the prevention of CDI
(Gerding et al., 2015; Zhang et al., 2015; Gerding
et al., 2018). For this reason, surveillance of both toxigenic and non-toxigenic strains in healthy and diseased
hosts is critical in understanding the aetiology and epidemiology of CDI, and for the early detection of emerging
strains.
Another factor contributing to C. difﬁcile pathogenicity
is the ability to form hardy endospores following exposure
to stress (Kochan et al., 2018). As an obligate anaerobe,
the formation of spores allows survival outside the host
and the versatility to persist in diverse environments.
Inoculated horse faeces can harbour viable C. difﬁcile for
4 years despite being exposed to the natural environment
(Båverud et al., 2003). These C. difﬁcile spores can also
withstand extreme temperatures and are impervious to
conventional
chemicals
including
alcohol-based
sanitizers commonly used in infection prevention and
control (Fawley et al., 2007; Hellickson and
Owens, 2008). This highlights the durability of C. difﬁcile
in both human and animal settings and is a cause for
major concerns for public health, and agricultural and animal husbandry practices. Despite 40 years of investigations, the infectious dose of C. difﬁcile in humans and
animals is not known, although murine models suggest

that this could be as low as 1 spore cm 2 in healthy mice
(Lawley et al., 2010). The process is further complicated
by the need for microbiota disruption prior to exposure
(Moono et al., 2016). It is therefore important to maximize
the detection of even small numbers of C. difﬁcile spores
present within samples until further investigation into
infectious dose.

Epidemiology
The earliest record of C. difﬁcile in equines was in 1984
(Ehrich et al., 1984); however, the ﬁrst suggestion of an
association with equine enterocolitis was proposed
3 years later following an outbreak in a group of diarrhetic
foals (Jones et al., 1987). To date, there have been
inconsistencies in the reported prevalence and perceived
impact of C. difﬁcile in horses (Diab et al., 2013a). Isolation of C. difﬁcile has long been associated with horses
with diarrhoea or acute colitis, with isolation rates ranging
from 5% to 90% (Båverud et al., 2003; Frederick
et al., 2009; Thean et al., 2011; Morsi et al., 2019).
The proportion of healthy adult horses that carry C. difﬁcile appears to be much lower. Earlier small-scale investigations of C. difﬁcile in the Northern hemisphere
returned relatively low detection rates (0%–4%),
(Madewell et al., 1995; Weese et al., 2001; Båverud
et al., 2003), while a single preliminary Australian study
failed to isolate C. difﬁcile from healthy horses (n = 112)
(Thean et al., 2011) This is in contrast to a larger study in
Ontario in 2011 which returned an overall faecal prevalence of 7.6% in healthy adult racehorses (n = 540) and,
more recently, smaller studies in Minnesota, USA
(n = 50) and Italy (n = 24) which recorded a 14% and
25% prevalence of C. difﬁcile respectively (Ossiprandi
et al., 2010; Medina-Torres et al., 2011; Shaughnessy
et al., 2018). Table 1 summarizes the prevalence of C.
difﬁcile identiﬁed in these key studies.
The prevalence of C. difﬁcile appears higher in foals,
with younger animals tending to harbour the bacterium at
higher rates, similar to other young animals (Båverud
et al., 2003; Morsi et al., 2019). In a 2003 study in
Sweden, C. difﬁcile was isolated from 29% of healthy
foals under the age of 14 days, and only 0.6% of foals
aged greater than 14 days (Båverud et al., 2003). This

© 2022 The Authors. Environmental Microbiology published by Society for Applied Microbiology and John Wiley & Sons Ltd.,
Environmental Microbiology, 24, 985–997

988 N. Hain-Saunders, D. R. Knight, M. Bruce and T. V. Riley
Table 1. Summary of key studies on the prevalence of C. difﬁcile in horses.

Location

Year(s)

Number tested

Australia

2007–2009

Canada (Ontario)

1998–1999

Canada (Ontario)
Italy

2006–2008
2007

62
112
55
255
31
47
540
24
18
30
286
49
42
227

Saudi Arabia

Sweden

2019

Unknown

273
51

USA (California)

1993

USA (Minnesota)
USA (Florida)

2011–2013
2003–2008

226
10
23
50
233

Health Status
Diarrhetic
Healthy
Diarrhetic
Healthy
Diarrhetic
Healthy
Healthy
Healthy
Healthy
Diarrhetic
Healthy
Diarrhetic
Healthy
Enteric disorders/on
antimicrobials
Healthy
Enteric disorders/on
antimicrobials
Healthy
Diarrhetic
Healthy
Healthy
Diarrhetic

Adult/
Foal

No. C. difﬁcile
positive (%)

Unknown
Unknown
Adult
Adult
Foal
Foal
Adult
Adult
Foal
Adult
Adult
Foal
Foal
Adult

14 (23%)
0 (0%)
7 (12.7%)
1 (0.4%)
11 (33.3%)
0
41 (7.59%)
6 (25%)
8 (44.4%)
7 (23.3%)
3 (1.1%)
11 (22.5%)
3 (7.1%)
23 (10.1%)

Adult
Foal

0
11 (21.57%)

Foal
Adult
Adult
Unknown
Foal

17 (8%)
9 (90%)a
1 (4.3%)
7 (14%)
11 (5%)

References
Thean et al. (2011)
Weese et al. (2001)

Medina-Torres et al. (2011)
Ossiprandi et al. (2010)
Morsi et al. (2019)

Båverud et al. (2003)

Madewell et al. (1995)
Shaughnessy et al. (2018)
Frederick et al. (2009)

a

Possible hospital outbreak.

trend was also identiﬁed in a 2019 study in Saudi Arabia
where all foals carrying C. difﬁcile (7.1% of healthy and
22.5% of diarrhetic foals) were aged <2 months, with C.
difﬁcile not isolated from any foal over this age (Morsi
et al., 2019).
It is difﬁcult to draw meaningful conclusions from these
variable results given the limited number of investigations, combined with geographical, methodological and
temporal differences. Nevertheless, there does appear to
be a tendency towards outbreaks and sporadic cases
rather than ongoing chronic or recurrent illness (Diab
et al., 2013b). Longitudinal studies further revealed the
transient nature of horse C. difﬁcile colonization, with an
overall prevalence of 5.4% compared to a cumulative
prevalence of 40% (Schoster et al., 2012). This was concordant with a recent Swiss study investigating C. difﬁcile
in horses with colic, and diarrhetic and healthy horses
where the cumulative prevalence (19%) appeared much
higher than single-day testing (10%), questioning the
need for multi-day sampling in at-risk horses or
suspected cases (Schoster et al., 2019).
This ephemeral pattern has been demonstrated in
other animals and adds to the complexity of CDI epidemiology and difﬁculty in comparing studies (Bandelj
et al., 2016). Furthermore, the opportunistic nature of C.
difﬁcile colonization and the need for both exposure and
commensal ﬂora disruption for the establishment of disease creates challenges in determining the signiﬁcance
of an asymptomatic state. Despite these apparent inconsistencies and knowledge gaps, it is evident that C.

difﬁcile in horses could potentially act as a reservoir for
zoonotic spread and further investigation is needed to
clarify this role.
Equine C. difﬁcile strains isolated in studies include
both novel strains as well as those identiﬁed in other animals, the environment and humans. Notably, in the 2011
Ontario study mentioned 76.5% of C. difﬁcile isolated
were strains previously isolated in humans locally, with
57.7% being RTs 001, 027 or 078, which have been
implicated internationally in epidemic outbreaks in
humans and other animals (Medina-Torres et al., 2011).
Concerningly, equine cases of infection with the highly
virulent RT 027 strain have also been identiﬁed elsewhere with severe outcomes (Songer et al., 2009).
Predisposing factors for CDI
Risk factors for CDI in horses centre around circumstances that disrupt the host’s native intestinal ﬂora, or
which create situations of higher exposure. Antimicrobial
exposure and hospitalization are the most recognized
risks and have long been associated with CDI across
human and animal populations alike (Deshpande
et al., 2013; Slimings and Riley, 2014).
Antimicrobial use
Antimicrobials contribute to disease by altering the number, diversity and relative composition of the host commensal gut ﬂora, allowing C. difﬁcile to colonize

© 2022 The Authors. Environmental Microbiology published by Society for Applied Microbiology and John Wiley & Sons Ltd.,
Environmental Microbiology, 24, 985–997

C. difﬁcile, One Health and horses
(Robinson and Young, 2010; Reeves et al., 2011). Studies suggest certain antimicrobials may also increase
adhesin (Denève et al., 2008) and toxin gene
(Drummond et al., 2003) expression in C. difﬁcile, leading
to increased pathogenicity.
CDI in horses has been associated with exposure to
an array of antimicrobials including β-lactams (penicillin,
ampicillin, cephalosporins), gentamicin, clindamycin,
erythromycin, rifampicin and trimethoprim/sulfonamides
(Båverud et al., 1997; Båverud et al., 1998; Arroyo
et al., 2004; Diab et al., 2013a; Morsi et al., 2019). Of
particular note is the association of CDI with the use of
ceftiofur, one of the antimicrobials most commonly used
in horses (Rodriguez et al., 2014). Ceftiofur is a veterinary third-generation cephalosporin, the human equivalent of which is also a known risk factor for CDI in
humans (Slimings and Riley, 2014). Ceftiofur can signiﬁcantly disrupt the bacterial ﬂora of the horse hindgut with
studies identifying a 75% reduction in lactobacilli and the
appearance of C. difﬁcile within 24 h of antimicrobial
administration (Harlow et al., 2013). This imbalance can
allow opportunists such as C. difﬁcile to colonize. Commensal bacteria in the horse gut are important for understanding C. difﬁcile colonization for several reasons.
First, it is believed that these bacteria compete for both
nutrients and adhesion sites. Second, studies have also
suggested that species such as lactobacilli alter their
environment, producing metabolites utilized by certain
bacteria and excluding others (Harlow et al., 2013). Commensal bacterial counts remain disrupted for at least
1 week after antimicrobial administration (Harlow
et al., 2013). This is an important consideration as longer
disruption increases the chance of exposure to pathogens such as C. difﬁcile while in a high-risk state.
In addition to direct administration, indirect exposure to
antimicrobials may also be important. Although not studied in horses, it has been estimated that between 15%
and 50% of antimicrobials administered to livestock
remain as residue in resulting manure with some thought
to persist for over a year (Chee-Sanford et al., 2009; Kim
et al., 2011; Berendsen et al., 2018; Filippitzi
et al., 2019). Tetracyclines, macrolides, quinolones and
lincosamide appeared to have the longest persistence in
manure and the environment (Berendsen et al., 2018).
Interestingly, the latter class includes clindamycin which
has been linked to a greater risk of communityassociated CDI (CA-CDI) development in humans
(Deshpande et al., 2013). Studies in horses have also
shown that mares of macrolide-treated foals have contracted CDI and hyperacute colitis due to the ingestion of
residual antimicrobials, and outbreaks of colitis on horse
farms due to feed contamination by tetracyclines have
also been documented (Båverud et al., 1998; Keir
et al., 1999).
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Hospitalization
While hospitalization is generally accepted as a risk factor for C. difﬁcile and CDI in horses, the primary source
of exposure remains less clear. Environmental sampling
at veterinary hospitals identiﬁed rough, hard to clean surfaces (such as concrete and mats), high trafﬁc zones,
and areas previously used by individuals with conﬁrmed
CDI as high-risk areas for transmission (Weese
et al., 2000). However, in a recent study, nosocomial
equine CDI was presented as an increasingly complex
and multifaceted issue (Weese et al., 2021). The nature
and severity of illness at admission, undeﬁned classiﬁcation of ‘hospital’ versus ‘community’ acquired cases in
an equine setting and extent of contact with treating veterinarians all add to the overall narrative and must be
considered in the identiﬁcation of preventative strategies
and infection control protocols.

Other factors
Diet changes, transportation and other causes of stress
in animals may act as risk factors for CDI in equine
populations (Båverud, 2002). Such inﬂuences have been
previously identiﬁed in cattle and are thought to disrupt
the gut ﬂora, providing a window of opportunity for C. difﬁcile to establish; however, the exact mechanisms and
the full impact are not known (Bandelj et al., 2016).
Despite this extensive list, it should be noted, however,
that cases of CDI with no obvious risk factors are common. This is particularly true in foals which may become
colonized within days of birth, but also in a proportion of
adult equine cases (Båverud et al., 2003). This wide
array of potential predisposing factors and uncertainty
shows the complexity of CDI and highlight the challenges
faced in controlling its impact.

Presentation, detection and diagnosis
Equine CDI can have a rapid onset, with a delay in treatment leading to signiﬁcant patient deterioration. With
reported mortality of up to 83% in conﬁrmed CDI cases
(Nomura et al., 2020), a need for timely investigation and
diagnosis based on a combination of clinical history, presentation and laboratory testing is apparent.
As with humans, the clinical presentation of CDI in
horses can vary in both clinical signs and severity.
Horses with CDI may exhibit episodes of watery diarrhoea, abdominal distension, fever, tachypnoea, tachycardia, changes to the mucous membranes and capillary
reﬁll times, as well as depression and anorexia (Weese
et al., 2006). Intestinal inﬂammation and lesion development are common in both foals and adult horses, with the
region thickened due to oedema, and characterized by
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haemorrhage, eruption and necrosis of the mucosa, and
pseudomembrane formation (Keel and Songer, 2006;
Diab et al., 2013b). These clinical signs and symptoms,
however, are common to a variety of aetiologies and are
insufﬁcient indicators alone for a presumptive diagnosis
of CDI. Differential diagnoses cover a diverse selection of
infectious agents such as Salmonella species, Equine
Coronavirus, Neorickettsia risticii and Clostridium perfringens (Shaw and Stämpﬂi, 2018). Laboratory identiﬁcation, therefore, plays an important role in diagnosis,
although this is not without its problems.
Standardized testing protocols do not exist across veterinary laboratories (Medina-Torres et al., 2010). Despite
progression in technology and laboratory systems in the
last few decades, the most optimal method for detection
of C. difﬁcile and subsequent diagnosis of CDI remains a
contentious issue across veterinary and human medical
ﬁelds (Fang et al., 2017). As with all clinical testing, a delicate balance must be struck between sensitivity and
speciﬁcity as well as efﬁciency and cost. In the case of
C. difﬁcile, however, the complexities of the pathogenesis of CDI, combined with the phenomenon of asymptomatic carriage, create a further obstacle, and the lines
between detection and diagnosis begin to blur. There are
currently three main laboratory testing methods utilized in
the detection of C. difﬁcile and diagnosis of CDI. These
include culture, enzyme-linked immunosorbent assays
and PCR. Ongoing research efforts into additional testing
options have, however, shown potential.

Culture with cell cytotoxin assay
Techniques involving culturing of C. difﬁcile from faecal
samples and testing isolates for toxin production are recognized as the gold standard for laboratory detection
(Planche et al., 2013). Due to the supposed difﬁculty in
culturing this bacterium (from which it gained its name),
and the low vegetative cell/high spore count in animal
faecal samples, various enrichment broths containing
antimicrobials are often utilized in addition to direct culture (Knight et al., 2014; Avberšek, 2017). This is
followed by sub-culture onto selective and differential
media such as cycloserine-cefoxitin fructose agar or
chromogenic agar (Avberšek, 2017).
Simple culturing C. difﬁcile is insufﬁcient to discriminate between toxin and non-toxin producing strains. Subsequent tests such as a cell culture cytotoxicity assay are
therefore required to determine toxigenicity and, in turn,
the capacity to cause disease. The long turnaround time
for growth (24–48 h) and toxin assays deem this
approach impractical for routine diagnostic use. Furthermore, C. difﬁcile culturing procedures across laboratories
are not standardized (Carroll, 2011). Culturing is

therefore generally reserved for epidemiological investigations and as a reference method (McDonald
et al., 2018).
Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assays (ELISAs) can
detect glutamate dehydrogenase (GHD), a highly conserved enzyme produced by all C. difﬁcile in faecal samples (Carman et al., 2012). This method is quick and
inexpensive; however, it lacks speciﬁcity to distinguish
between toxigenic and non-toxigenic strains. Several
commercial EIA kits have been developed and are utilized in diagnostic laboratories. Assessment of the most
commonly used kit for equine C. difﬁcile in North America
showed a sensitivity of 86% and speciﬁcity of 96%; however, this is likely variable across competing products
(Medina-Torres et al., 2010). ELISA kits aimed at
detecting the presence of toxins A and B in faecal samples (with or without GHD) have also been developed.
Given the requirement for toxin production for disease
development, as well as the ease and availability of
ELISA kits, these are now often routinely used as the
diagnostic standard despite lower sensitivity and with
many lacking formal validation in equine settings (Ramos
et al., 2020).
PCR
PCR is being increasingly utilized in commercial laboratories as a quick and very sensitive method for the detection of C. difﬁcile, despite greater expense compared to
ELISA (Planche et al., 2013). This method detects the
presence of C. difﬁcile genes or its toxin genes within the
sample. Caution must be employed for the diagnosis of
disease as this method does not identify toxins, just toxin
genes, and fails to distinguish between transient carrier
and
permanent
colonization
states
(OliverEspinosa, 2018). For this reason, CDI overdiagnosis
through the reliance on PCR testing alone has become a
concern. In human studies, while negative predictive
values remain high (96%), CDI positive predictive values
can be as low as 46% and are highly dependent on disease prevalence (Lee et al., 2021). This highlights a need
to better understand the extent of asymptomatic carriage
within a population and the role it plays in CDI development and dissemination in parallel to decisions regarding
diagnostic methods.
Future developments in diagnostics
As knowledge of the bacterium and disease progresses,
the possibility of additional diagnostic methods increases.
For example, a recent study of blood biomarkers in
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407 Arabian horses identiﬁed increased haptoglobin,
serum amyloid A, neopterin and procalcitonin in horses
with active C. difﬁcile enterocolitis, as well as evidence of
oxidative stress markers (El-Deeb et al., 2020). Although
limited, this investigation into additional C. difﬁcile markers
shows the potential for future paths in CDI detection.
To overcome the shortfalls of current testing methodologies, a multistep testing regime may assist to increase the
sensitivity and speciﬁcity of individual tests. Although speciﬁc recommendations in equine testing are yet to be
made, the call for a two-step diagnostic method for animal
C. difﬁcile assays is repeatedly echoed throughout the literature. For example, researchers in the evaluation of pig
testing recommended the successive use of both real-time
PCR and toxigenic culture to overcome poor performance
and inconsistency in EIA kits (Keessen et al., 2011), while
Fathy et al. (2021) promote a combination of conventional
culture followed by molecular methods to reduce falsenegative results (Fathy et al., 2021).
There is, however, some concern regarding the methodologies currently utilized in equine C. difﬁcile detection
and CDI diagnosis. First and foremost is the frequent use
of methods developed for human samples, but not yet
validated
for
equine
samples
(Medina-Torres
et al., 2010). This leaves many questions regarding the
appropriateness of use and comparative performance in
animal investigations and highlights the need for further
analysis and species-speciﬁc testing.
Furthermore, limited understanding of the toxins identiﬁed in equine CDI may have an impact on laboratory
diagnosis. While it is accepted that C. difﬁcile toxins A and
B are associated with cytopathic damage, the implications
of the different combinations of toxins are not well known,
creating issues in laboratory protocols that may focus only
on the detection of a single toxin. In addition, the role of
binary toxin in equine disease is not well understood and
detection is not usually included in routine testing regimes.
On a ﬁnal note, as with all testing regimes, it is important
that decisions on testing and diagnosis do not ignore practical issues such as whether the test outcome will have an
impact on clinical decision making and alter the treatment
strategy. As suggested by the international Equine Colitis
Research Group, to make the most appropriate choice
regarding how to test and, indeed, whether or not to test in
the ﬁrst place, the prevalence in healthy populations and
the positive predictive value of the test must be known
(International Equine Colitis Research Group, 2020). Perhaps more studies in a research setting utilizing the ‘gold
standard’ method of toxigenic culture are required.
Treatment and prophylaxis
On initial presentation, equine CDI cases with diarrhoea
and endotoxemia associated with the disease can often

991

represent an immediate danger that can lead to dehydration, electrolyte imbalances and haematological abnormalities (Weese et al., 2006; Nomura et al., 2020). Fluid
and electrolyte therapy aimed at restoring blood volume
and biochemistry is often carried out to stabilize the
patient, with nonsteroidal anti-inﬂammatory agents
administered to minimize deleterious inﬂammatory
responses (Shaw and Stämpﬂi, 2018). Treatment to
avoid complications associated with CDI is also important
in the care of equine cases, including hoof cryotherapy to
prevent laminitis (Shaw and Stämpﬂi, 2018).
These initial treatments, however, focus on correcting
the effects of the infection rather than controlling the bacteria and toxins, themselves. In equine cases, a combination
of antimicrobial and supportive therapies, therefore, remain
central in the overall treatment of CDI. Metronidazole is
often the ﬁrst-line choice in the treatment of CDI in horses,
with administration associated with survival (Weese
et al., 2006). Concerningly, the existence of metronidazole
resistance has been noted in some equine and human
studies, highlighting the need for multiple avenues for
treatment to be available (Boekhoud et al., 2020). Vancomycin may be utilized in cases where the infecting strain
of C. difﬁcile shows resistance to metronidazole; however,
this should be avoided where possible due to the heavy
reliance on vancomycin in human treatment and the rise of
vancomycin resistance (Schoster and Staempﬂi, 2016).
This thinking is being challenged with the increase in C.
difﬁcile resistance to metronidazole and a range of other
antimicrobials over the last two decades (Peng
et al., 2017). The AMR situation has become so dire that
in both 2013 and 2019, the United States CDC listed C.
difﬁcile in the top ﬁve infectious agents posing an urgent
threat to the community based on the apparent increase in
AMR in circulating strains (Centers for Disease Control
and Prevention, 2019).
Adjunctive therapies have also been developed with
varying results. Bismuth subsalicylate is thought to prevent attachment of C. difﬁcile to intestinal cells by coating
the mucosa as well as providing antimicrobial and antiinﬂammatory activity against C. difﬁcile (Mallicote
et al., 2012; Pitz et al., 2015). Despite its common use in
diarrhetic horses, its true effectiveness in horse infections
of the large intestine has been questioned due to the
large volume of contents with little species-speciﬁc testing (McConnico, 2015). Di-tri-octahedral smectite also
binds and neutralizes C. difﬁcile toxins A and B in vitro,
however, while commercial products (such as BioSponge) are successfully utilized in the general treatment
of diarrhetic horses, C. difﬁcile speciﬁc in vivo testing is
lacking (Weese et al., 2003; Hassel et al., 2009; OliverEspinosa, 2018).
Beyond traditional treatment methods, alternative
microbiota restorative therapies are also being developed
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aimed at re-establishing commensal microbiota diversity
to resemble that of a ‘healthy’ individual. Faecal microbial transplantation (FMT) transfers faecal matter from
healthy donors into the gastrointestinal tracts of CDI
affected patients (Kelly et al., 2015). This has recently
gained popularity in the treatment of recurrent human
CDI with cure rates of 87%–90% (Kelly et al., 2015; van
Beurden et al., 2017). The concept of FMT is not new in
the animal setting. In its most basic form coprophagia,
where one individual consumes the faeces of another, is
commonplace between foals and their dams as an important process in establishing ‘normal’ gut bacteria during
infancy (Quercia et al., 2019). The effects of this on C.
difﬁcile and CDI have not been exclusively investigated.
Transfaunation, as FMT is also known in animals, is
well established in the treatment of general gastrointestinal ailments in livestock, including horses, although primarily anecdotal data exists for the latter (Feary and
Hassel, 2006; Bakken, 2009). In recent years, better
studies into the beneﬁts of FMT in horses have emerged
with promising results (McKinney et al., 2021). While
large-scale studies in horses and other animals have not
been done, isolated cases of treatment in marmosets
and dogs have been largely successful (Yamazaki
et al., 2017; Sugita et al., 2019). It is clear that much
more needs to be done to enable FMT to become a
mainstream treatment option in horses. A meeting of the
International Equine Colitis Research Group in 2020 cited
a lack of robust clinical studies into FMT in horses as a
limiting factor in progressing this therapy, advising that
many questions remain concerning longevity, screening
and best practice protocols in horses (International
Equine Colitis Research Group, 2020). The group also
highlighted a gap in knowledge regarding the horse
microbiome as a whole and a need for targeted investigations into key characteristics of horses affected by infectious agents such as C. difﬁcile.
Preventative therapies may also play an important role
in minimizing the effects of CDI in the future; however, to
date success has been limited. Probiotics have generated some interest although with varied and inconsistent
results (Schoster et al., 2015). Schoster et al. (2014)
suggested that this inconsistency may have been a result
of strain and dosage selection with some questions surrounding the quality control of commercial products.
Despite this, a small number of speciﬁc probiotic agents
have shown promising results. Lactobacillus reuteri
reduces the adhesion of C. difﬁcile to epithelial cells and
signiﬁcantly reduces the number of clostridial cells in the
faeces of horses (Dicks et al., 2015). Similarly, Saccharomyces boulardii has also shown potential in the prevention of equine CDI following success in humans
(Desrochers et al., 2005; Boyle et al., 2013; Carstensen
et al., 2018). This microorganism releases proteases that

digest C. difﬁcile toxin A, reduce its ability to bind to host
intestinal cells and interfere with host cell signalling to
reduce damaging inﬂammatory responses (Castagliuolo
et al., 1996; Chen et al., 2006). Vaccines for animals or
humans are yet to be developed although a number have
progressed to phases II and III trials (Riley et al., 2019). It
is clear that further investigations into prevention and
alternative treatments for CDI in horses are required.
A changing landscape and call for a One Health
approach
Although traditionally considered a healthcare-related disease, cases of CA-CDI are becoming increasingly common, now accounting for up to 50% of all human CDI
cases (Ofori et al., 2018). Furthermore, studies have
reported that one-third of patients with CA-CDI have no
apparent exposure to traditional risk factors of hospitalization or antimicrobials (Mooney et al., 2008). The driving
factors behind the shift towards CA-CDI are not well
understood, making infection prevention and control, and
establishing effective eradication programs challenging.
To date, C. difﬁcile has been detected in a diverse
range of sources from compost and lawns to root vegetables and livestock (Moono et al., 2017; Lim et al., 2018a;
Lim et al., 2018b). The presence of C. difﬁcile in production animals has been investigated, with evidence of
overlap of strains seen in animals and humans (Songer
et al., 2009; Medina-Torres et al., 2011; Knight and
Riley, 2013). The emergence of human disease caused
by strains previously only seen in animals also adds to
mounting evidence that CDI may be zoonotic, highlighting a need for a holistic One Health approach to understand and control this disease (Knight et al., 2015b;
Rodriguez et al., 2016).
The ‘One Health’ paradigm recognizes the relationship
between human health, animal health and the environment. It highlights the need to review all factors contributing to a health issue in attempts to control, prevent and
treat disease. The ubiquitous nature of C. difﬁcile makes
a One Health approach vital to public health planning.
Interaction between the main constituents inﬂuencing C.
difﬁcile transmission (seen in Fig. 2) is extensive and
complicated. Horses represent an interesting addition in
the C. difﬁcile story, with overlapping domains of production animal, companion animal and non-domesticated
populations. The potential for dissemination of C. difﬁcile
encompasses transfer through interaction, consumption
and indirectly through exposure to horse manure. In
countries such as Australia, with an estimated 400 000
feral horses, there is also signiﬁcant potential for dissemination at the wildlife–livestock–human interface through
interaction with other wild and native species, as well as
dispersal through shared water sources and possible
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Fig. 2. The proposed interaction of elements in C. difﬁcile
dispersion.

interaction
with
free-range
livestock
(Csurhes
et al., 2016). To date, C. difﬁcile in feral horses and the
role they play in dispersal has not been investigated. It
was previously noted that commercially available animal
manures and compost showed traces of C. difﬁcile. Local
horse manure is readily available for use in domestic and
market gardens, and on farms is often furrowed back into
paddocks allowing the potential for the spread of any
existing C. difﬁcile spores into the community. This creates a potential pathway for transfer between horses and
humans.
Furthermore, the emergence of C. difﬁcile AMR in both
human and animal strains and the possibility of bidirectional resistance gene transfer between the two add a further complication to the system (Knetsch et al., 2018).
Studies have shown horse derived C. difﬁcile strains
show high resistance to commonly used antimicrobials
such as ceftiofur and gentamicin, suggesting AMR may
be inﬂuenced by their use (Rodriguez et al., 2014). Injudicious use of antimicrobials in human healthcare, veterinary practices and farming has come under great
scrutiny for its contribution to AMR and the spread of
infectious disease. In 2015, the World Health Assembly
identiﬁed AMR as a critical issue, endorsing the development of a global action plan to tackle this problem. In
addition, in 2013 and 2019, the US Centers for Disease
Control and Prevention identiﬁed C. difﬁcile in the top ﬁve
microorganisms posing an urgent threat to public health
due to its developing AMR (Centers for Disease Control
and Prevention, 2019). Given the current global crisis of
AMR and the pervasiveness of C. difﬁcile, it is vital that
the health and science communities start to look outside
their immediate ﬁelds for solutions. For this reason,
investigations into the aetiology and epidemiology of C.
difﬁcile in non-traditional sources are required.

The way forward
Despite promising developments in the understanding of
equine C. difﬁcile, a lack of validation for species-speciﬁc
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diagnostic testing and treatment, as well as the ongoing
threat of AMR, creates challenges in the ﬁght against
CDI. The implications of asymptomatic carriage on the
dispersal of the bacterium also remains elusive and strain
characterization and molecular investigation may prove
crucial for a true appreciation of the C. difﬁcile epidemiology to assist in tracing the ﬂow through horse populations
and the community as a whole. As the links between C.
difﬁcile in animals, humans and the environment become
increasingly apparent, a more efﬁcient approach to antimicrobial surveillance, stewardship and AMR investigations is needed for long-term sustainability. A One Health
approach and further appreciation of the possible
sources of C. difﬁcile are therefore vital to the development of infection prevention and control strategies, to
minimize transmission risk as well as generate protocols
for optimal antimicrobial use.
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